Histogenesis of Experimentally Produced Keloids

Mancini, R. E.; Quaife, J V

doi:10.1038/jid.1962.29

Cited by 71 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 The exact cause and pathogenesis of keloid development remain unclear, although both environmental factors and genetic disposition are contributory. 3,4 Niessen et al aptly quote, "the less that is known about a disease, the more therapeutic modalities seem to be available, with, in general, unsatisfying results." 3 This universal medical truth certainly applies to keloids.…”

mentioning

confidence: 97%

A Primary Protocol for the Management of Ear Keloids: Results of Excision Combined with Intraoperative and Postoperative Steroid Injections

Rosen

Patel

Freeman

et al. 2007

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 97%

A Primary Protocol for the Management of Ear Keloids: Results of Excision Combined with Intraoperative and Postoperative Steroid Injections

Rosen

Patel

Freeman

et al. 2007

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…The specificity of SF-ELP is two part and is provided by the drug emodin and the SF coating. As previously stated, keloids overexpress RTK and are targeted by emodin, while the overexpression of the muco-polysaccharides over the cell surface would have attraction for the SF (Berman and Bieley 1995; Mancini and Quaife 1962). …”

Section: Emodin Efficacy and Specificitymentioning

confidence: 94%

“…They are characterized as raised pathological scars, causing pain and persistent itching, and are considered to be benign dermal tumors (Rockwell et al 1989; Ehrlich et al 1994; Niessen et al 1999). Chronic dermal wounds consist of fibroblasts that overproduce collagen and chondroitin sulfate, have high contractile activity, high levels of secreted cytokines, and are similar to tumors in overexpression of RTK, a transmembrane receptor that binds to growth factors such as fibroblast growth factor (FGF) (Mancini and Quaife 1962; Berman and Bieley 1995). Assessment of modified liposomes on this cell line will aid in characterization of adhesion targeting and drug specificity.…”

Section: Introductionmentioning

confidence: 99%

Silk-fibroin-coated liposomes for long-term and targeted drug delivery

Gobin¹,

Rhea²,

Newman³

et al. 2006

International Journal of Nanomedicine

View full text Add to dashboard Cite

Many barriers to drug delivery into a tumor site require careful consideration when designing a new drug. In this study, the adhesive targeting and drug specificity of modified liposomal vesicles on human-scar-producing cells, keloid fibroblasts, were investigated. Keloids express abundant levels of mucopolysaccharides and receptor tyrosine kinase (RTK). In this report, the structural properties, drug release kinetics, and therapeutic availability of silkfibroin-coated, emodin-loaded liposomes (SF-ELP), compared with uncoated, emodin-loaded liposomes (ELP), were investigated. SF-ELP had a highly organized lamellae structure, which contributed to 55% of the liposomal diameter. This modified liposomal structure decreased emodin release rates by changing the release kinetics from a swelling and diffusional process to a purely diffusional process, probably due to steric hindrance. SF-ELP also increased adhesion targeting to keloid fibroblasts. Increased retention of SF-ELP is most likely due to the interaction of the fibrous protein coating around the ELP with the pericellular molecules around the cell. SF-ELP also decreased survival rate of keloids that expressed high levels of RTK. These results demonstrated that SF-ELP enhanced emodin delivery by improved diffusion kinetics and specific cell targeting.

show abstract

“…In 1962, Mancini and Quaife 17 made the distinction between keloid and hypertrophic scarring in the way that we understand it today. In 1973, Madden and Peacock 18 provided the first histological understanding of keloid and hypertrophic scarring.…”

Section: History Of Hypertrophic Scarring and Pressure Garment Therapymentioning

confidence: 99%

Pressure garment to prevent abnormal scarring after burn injury in adults and children: the PEGASUS feasibility RCT and mixed-methods study

Moiemen

Mathers

Jones

et al. 2018

Health Technol Assess

View full text Add to dashboard Cite

Background Eleven million people suffer a fire-related injury worldwide every year, and 71% have significant scarring. Pressure garment therapy (PGT) is a standard part of burn scar management, but there is little evidence of its clinical effectiveness or cost-effectiveness. Objective To identify the barriers to, and the facilitators of, conducting a randomised controlled trial (RCT) of burn scar management with and without PGT and test whether or not such a trial is feasible. Design Web-based surveys, semistructured individual interviews, a pilot RCT including a health economic evaluation and embedded process evaluation. Setting UK NHS burns services. Interviews and the pilot trial were run in seven burns services. Participants Thirty NHS burns services and 245 staff provided survey responses and 15 staff participated in individual interviews. Face-to-face interviews were held with 24 adult patients and 16 parents of paediatric patients who had undergone PGT. The pilot trial recruited 88 participants (57 adults and 31 children) who were at risk of hypertrophic scarring and were considered suitable for scar management therapy. Interviews were held with 34 participants soon after recruitment, with 23 participants at 12 months and with eight staff from six sites at the end of the trial. Interventions The intervention was standard care with pressure garments. The control was standard care comprising scar management techniques involving demonstration and recommendations to undertake massage three or four times per day with moisturiser, silicone treatment, stretching and other exercises. Main outcome measures Feasibility was assessed by eligibility rates, consent rates, retention in allocated arms, adherence with treatment and follow-up and completion of outcome assessments. The outcomes from interview-based studies were core outcome domains and barriers to, and facilitators of, trial participation and delivery. Results NHS burns services treat 2845 patients per annum (1476 paediatric and 1369 adult) and use pressure garments for 6–18 months, costing £2,171,184. The majority of staff perceived a need for a RCT of PGT, but often lacked equipoise around the research question and PGT as a treatment. Strong views about the use of PGT have the potential to influence the conduct of a full-scale RCT. A range of outcome domains was identified as important via the qualitative research: perceptions of appearance, specific scar characteristics, function, pain and itch, broader psychosocial outcomes and treatment burden. The outcome tools evaluated in the pilot trial did not cover all of these domains. The planned 88 participants were recruited: the eligibility rate was 88% [95% confidence interval (CI) 83% to 92%], the consent rate was 47% (95% CI 40% to 55%). Five (6%) participants withdrew, 14 (16%) were lost to follow-up and 8 (9%) crossed over. Adherence was as in clinical practice. Completion of outcomes was high for adult patients but poorer from parents of paediatric patients, particularly for quality of life. Sections on range of movement and willingness to pay were found to be challenging and poorly completed. Limitations The Brisbane Burn Scar Impact Profile appears more suitable in terms of conceptual coverage than the outcome scales that were used in the trial but was not available at the time of the study. Conclusions A definitive RCT of PGT in burn scar management appears feasible. However, staff attitudes to the use of pressure garments may lead to biases, and the provision of training and support to sites and an ongoing assessment of trial processes are required. Future work We recommend that any future trial include an in-depth mixed-methods recruitment investigation and a process evaluation to account for this. Trial registration Current Controlled Trials ISRCTN34483199. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 36. See the NIHR Journals Library website for further project information

show abstract

Histogenesis of Experimentally Produced Keloids

Cited by 71 publications

References 12 publications

A Primary Protocol for the Management of Ear Keloids: Results of Excision Combined with Intraoperative and Postoperative Steroid Injections

A Primary Protocol for the Management of Ear Keloids: Results of Excision Combined with Intraoperative and Postoperative Steroid Injections

Silk-fibroin-coated liposomes for long-term and targeted drug delivery

Pressure garment to prevent abnormal scarring after burn injury in adults and children: the PEGASUS feasibility RCT and mixed-methods study

Contact Info

Product

Resources

About